<?xml version="1.0" encoding="UTF-8"?>
<ref id="B24-ijerph-17-01686">
 <label>24.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Marlow</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Kuriyakose</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Mesaros</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Han</surname>
    <given-names>H.H.</given-names>
   </name>
   <name>
    <surname>Tomlinson</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Faust</surname>
    <given-names>S.N.</given-names>
   </name>
   <name>
    <surname>Snape</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Pollard</surname>
    <given-names>A.J.</given-names>
   </name>
   <name>
    <surname>Finn</surname>
    <given-names>A.</given-names>
   </name>
  </person-group>
  <article-title>A Phase III, open-label, randomized multicenter study to evaluate the immunogeneicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4 year-old healthy children in the UK</article-title>
  <source>Vaccine</source>
  <year>2018</year>
  <volume>36</volume>
  <fpage>2300</fpage>
  <lpage>2306</lpage>
  <pub-id pub-id-type="pmid">29576304</pub-id>
 </element-citation>
</ref>
